Transmembrane mucins, MUC4 and MUC16 are associated with tumor progression and metastatic potential in human pancreatic adenocarcinoma. We discovered that miR-200c interacts with specific sequences within the coding sequence of MUC4 and MUC16 mRNAs, and evaluated the regulatory nature of this association. Pancreatic cancer cell lines S2.028 and T3M-4 transfected with miR-200c showed a 4.18 and 8.50 fold down regulation of MUC4 mRNA, and 4.68 and 4.82 fold down regulation of MUC16 mRNA compared to mock-transfected cells, respectively. A significant reduction of glycoprotein expression was also observed. These results indicate that miR-200c overexpression regulates MUC4 and MUC16 mucins in pancreatic cancer cells by directly targeting the mRNA coding sequence of each, resulting in reduced levels of MUC4 and MUC16 mRNA and protein. These data suggest that, in addition to regulating proteins that modulate EMT, miR-200c influences expression of cell surface mucins in pancreatic cancer.
Introduction
MicroRNAs (miRNAs) are small (~20-22 nucleotides) noncoding RNAs that regulate gene expression by interacting with either the 3' untranslated region (3' UTR) or coding region of target mRNAs. Expression of targeted gene products are affected by miRNA induced mRNA degradation or inhibition of translation [1] . Altered expression of miRNAs in cancer results in tumor promoting and tumor suppressing functions. For example, miR-155, miR-17-5p and miR-21 have known oncogenic activities [2, 3] , whereas, miR-15a, miR-16-1, let-7 and miR-145 function as tumor suppressors [4] [5] [6] [7] [8] [9] . It has been shown that miR-200c is differentially expressed in pancreatic cancer, where high expression was associated with better survival and low expression is associated with worse survival [10] . Overexpression of miR-200c inhibits cancer cell invasion by modulating factors important in EMT [10] . Ectopic expression of miR-200c induces higher levels of E-cadherin in breast and pancreatic cancer cells through the direct targeting of transcription factor 8 (TCF8/ ZEB1), a negative regulator of E-cadherin [11] [12] [13] [14] . Therefore, cells with high levels of miR-200c have a more epithelial and less mesenchymal phenotype that may impact metastasis.
Recently, overexpression of miR-200c was shown to inhibit melanoma tumor progression and drug resistance [15] .
Aberrant expression of mucin glycoproteins is associated with pancreatic cancer progression to metastasis. The transmembrane mucins, MUC4 and MUC16, are aberrantly overexpressed in many adenocarcinomas, including human pancreatic cancer [16] [17] [18] . The MUC4 mucin is a large glycoprotein expressed by epithelial cells in a variety of tissues. MUC4 is not expressed in the normal pancreas, but is aberrantly expressed in a high percentage of premalignant and malignant pancreatic lesions [16, 19] . MUC4 promotes cancer growth and metastasis in part through interaction with the HER2 oncoprotein [20, 21] . MUC16 (CA125) is a high molecular weight mucin glycoprotein normally expressed in ocular surface, respiratory tract and reproductive organs containing epithelial cells [22] . CA125, an epitope on MUC16, is used as a tumor marker for detection of ovarian cancer in sera of patients [23] and MUC16 influences ovarian cancer growth and metastasis [24] . Increased expression of MUC16 is also observed in human pancreatic cancer [17, 18] , and we have recently shown that there is increased expression in metastatic lesions of pancreatic cancer patients [25] .
We report here that miR-200c interacts with specific sequences within the coding sequence of MUC4 and MUC16 mRNAs and regulates their levels of expression. Higher expression of transmembrane mucins and loss of miR-200c are highly associated with metastatic characteristics of cancer cells.
Materials and Methods

Cell lines and culture
Human pancreatic cancer cells Capan-1 (American Type Culture Collection, ATCC), S2.007, S2.013, S2.020, S2.028 [26] , HPAF (Generous gift from R.S. Metzgar, Department of Microbiology and Immunology, Duke University Medical Center, Durham. North Carolina), and T3M-4 (Kind gift from Tetsuro Okabe, University of Tokyo, Japan) were grown in Dulbecco's Modified Eagle's Medium (DMEM) (Hyclone, Logan, UT, USA), supplemented with 10% Fetal bovine serum (Valley Biomedical Inc., Winchester, VA, USA), 100 µg/mL streptomycin and 100 units/mL penicillin (Mediatech Inc., Manassas, VA, USA) and incubated at 37°C with 5% CO 2 in a humidified incubator.
microRNA isolation and Real time-PCR (RT-PCR) analysis of miR-200c
miRNA were extracted from pancreatic cancer cells using mirVana miRNA isolation kit (Ambion, Carlsbad, CA, USA). Expression of miR-200c was quantified using TaqMan MicroRNA assay kit (ABI, Carlsbad, CA, USA) according to the manufacturer's protocol.
miRNA-200c overexpression in S2.028 and T3M-4 pancreatic cancer cell lines
Oligonucleotides of the primary transcript of miR-200c were cloned into pSilencer 4.1-CMV plasmid (Ambion, Carlsbad, CA, USA) (Table S1 ) to establish a stable expression vector. Cells were seeded at 75 x10 3 cells per well (12-well plate) the day prior to transfection, and 1 µg plasmid was transfected into the cells the following day using Lipofectamine LTX with PLUS reagent (Invitrogen life technologies, Carlsbad, CA, USA) according to the manufacturer's protocol. Cells were placed under selection with G418 (200µg/ml) 48 hours after transfection. Clones were subsequently picked and analyzed for miR-200c expression in the S2.028 cell line (clone 7), while a polyclonal selected population was utilized for the T3M-4 cell line. Cells transfected with scrambled sequence containing vector from the kit (Ambion, Carlsbad, CA, USA) served as a negative control. Expression of miR-200c was quantified using TaqMan MicroRNA assay kit (ABI, Carlsbad, CA, USA) according to the manufacturer's instructions. U6 rRNA was used as an internal control. The fold-change in expression was calculated by using the 2 -ΔΔCt method [27] .
Methylene Blue Cell Proliferation Assay
Cell proliferation was assayed using a methylene blue cell dye as previously described [28] 
Real-time PCR (RT PCR) analysis of mucin expression
Total RNA was isolated from S2.028 and T3M-4 cells using TRI Reagent (Molecular Research Center, Cincinnati, OH, USA) according to the manufacturer's instructions. cDNA was synthesized by using Verso cDNA kit (Thermo, Fisher Scientific, Waltham, MA, USA). Analysis of MUC1, MUC4, MUC16 and GAPDH mRNA levels were performed with SYBR Green PCR master mix (ABI, Carlsbad, CA, USA). The following primers were used for RT-PCR: MUC1, F-5-CTGCTCCTCACAGTGCTTACAGTTG-3;
R-5-ACCAA ATCCGTTGACTCCGACCTT-3. Each experiment was carried out in triplicate. Differences in mucin gene expression, expressed as fold-changes, were calculated using the 2 -ΔΔCt method using GAPDH as internal control.
Immunoblot analysis of Mucins
SDS-Agarose gel electrophoresis was used to analyze mucin expression as described previously [29] . Cells expressing miR-200c or a scrambled control were harvested and protein was extracted using NP-40 cell lysis buffer (150mM NaCl, 50mM Tris-HCl, 1% NP-40, pH8.0) supplemented with protease inhibitors (Promega, Madison, WI, USA). Cell lysates (50-100 µg proteins) were resolved on SDS (0.1%) -Agarose (2%) gel electrophoresis and transferred to PVDF membrane. Membranes were blocked in 5% non-fat dry milk powder in Tris-buffered saline (150mM NaCl, 50mM Tris-HCl) with 0. 
Vector constructs
ORF regions of MUC16 and MUC4 mRNA that were predicted to interact with miR-200c were synthesized and inserted into pMIR-REPORT TM miRNA Expression Reporter Vector system (ABI, Carlsbad, CA, USA) using the SpeI and HindIII restriction sites (New England BioLabs, Ipswich, MA, USA). Wild type and mutant MUC4 and MUC16/miR-200c interactions sequences were synthesized and used in this study (Table S1 ). Mutations within potential miR-200c binding sites were generated by nucleotide replacement of wild type sequence to inhibit miR-200c binding. The insertion and orientation of the fragment were confirmed by sequence analysis. The plasmids were designated pMIR-REPORT TM -wild (MUC16 and MUC4 wt) and pMIR-REPORT TM -mutant (MUC16 and MUC4 mt) (Table S1 ).
Transfection and Luciferase assays
Pancreatic cancer (S2.028 and T3M-4) cells were cultured in a 6 well plate and transiently transfected at 60-80% confluence with the plasmids indicated above using the Lipofectamine TM 2000 reagent (Invitrogen life technologies, Carlsbad, CA, USA) as per the manufacturer's instructions. Luciferase activity was measured by using Luciferase Reporter Assay systems (Promega, Madison, WI, USA), 48 h after transfection. Luciferase assays were carried out according to the manufacturer's instructions on a 96 well plate reader (Polar Star Optima Microplate Reader, Offenburg, Germany). All values were presented as Mean ± SEM of relative luciferase units (RLU) from three independent experiments performed in triplicates. An unpaired t-test (two-tailed) was performed for statistical analysis using the GraphPad PRISM® Version 5.0 program. Differences with a p value < 0.05 were considered statistically significant. 
MUC4 and MUC16 expression is suppressed by miR-200c
We assessed the ability of miR-200c to regulate membrane bound mucins by expressing miR-200c (pSilencer 4.1-CMVmiR-200c) in pancreatic cancer cell lines S2.028 and T3M-4. There was a dramatic reduction of MUC4 protein in S2.028-miR200c (1.7 fold) and T3M-4-miR-200c (4.46 fold) cells relative to control cells (Figure 2A and 2B) . Similarly, there was a significant reduction in MUC16 protein (high and low molecular weight isoforms) in S2.028-miR200c (18.1 and 5.9 fold respectively) and T3M-4-miR-200c (5.2 and 6.1 fold respectively) cells as compared to control cells ( Figure 3A and 3B).
miR-200c targets transcriptionally membrane bound mucins MUC4 and MUC16
We also observed a significant reduction of both MUC4 and MUC16 mRNA levels in miR200c expressing cell lines. MUC4 transcripts were reduced 4.18 and 8.50 fold in S2.028-miR200c and T3M-4-miR200c respectively ( Figure 4A and 4B) compared to control cells. MUC16 transcripts were reduced 4.68 and 4.82 fold in S2.028-miR200c and T3M-4-miR200c respectively, compared to control cells ( Figure 4C and 4D) . 
miR-200c directly targets the coding sequences of MUC4 and MUC16
We evaluated binding of miR-200c to the putative target sequence by cloning the regions containing human MUC4 and MUC16 coding sequences into the pMIR-Luciferase reporter vector (pMIR-MUC4 and MUC16 wt). Negative controls were produced in which the pMIR-MUC4 and MUC16 sequences were mutated at the putative binding sites for miR-200c and the mucins (pMIR-MUC4 and MUC16 mt) ( Figure 6A ). S2.028 and T3M-4/miR-200c cells were transiently transfected with plasmid DNAs encoding vector alone, wild type MUC4 and MUC16 sequences in the vector, and mutant type MUC4 and MUC16 sequences in the vector. We observed that luciferase reporter activity was significantly suppressed for both MUC4 and MUC16 in S2.028 and T3M-4 miR-200c cells transfected with wild type sequence vectors as compared to vector control transfected cells (***p<0.0001, MUC4-wt, MUC16-wt vs vector 
Discussion
In the present study, we demonstrate for the first time that a mirR-200c targets high molecular weight mucin glycoproteins by targeting their coding sequence for degradation or translational inhibition. Specifically, miR-200c targets MUC4 and MUC16 exon sequences to regulate mRNA and protein levels for each of these mucins. We have shown that miR-200c is differentially expressed in pancreatic cancer cells. Yu et al observed a significantly higher survival rate in pancreatic cancer patients with higher levels of miR-200c compared to those with lower levels of miR-200c [10] . Previous work has also shown that pancreatic cancer cells overexpressing miR-200c exhibit reduced invasion and increased levels of Ecadherin mRNA, suggesting that miR-200c plays an inhibitory role in pancreatic cancer growth and invasion [10] . Overexpression of miR-200c increased the rate of proliferation in SUIT-2, PANC-1 and KP-3 pancreatic cancer cells [10] , however, we observed reduced cell proliferation of S2.028 miR-200c expressing cells, suggesting that the cell growth properties differentially regulated by miR-200c are context dependent. MiR-200c has been described as a powerful master regulator of epithelial-to-mesenchymal transition in breast and ovarian cancer cells through altering the expression of ZEB1 and E-cadherin by binding to 3' UTRs and driving degradation or blocking translation of the target mRNA [11] [12] [13] [14] . Restoration of miR-200c expression in highly aggressive breast and ovarian cancer cells significantly reduced invasion, migration and drug resistance of these tumor types [30, 31] . These reports suggest that introduction of miR-200c into cancer cells could reverse tumor progression and provide a novel treatment strategy.
A majority of reports show that miRNAs target the noncoding 3'UTR of mRNAs; however, recent reports have shown that miRNAs can also target coding sequences of mammalian genes. We report here that miR-200c targets exon coding sequences in transcripts of high molecular weight mucin glycoproteins MUC4 and MUC16 and reduces mRNA and protein expression. Similarly, Huang et al, reported that miR-181a targets a large number of zinc finger genes by binding to their coding sequences [32] and Duursma et al reported that miR-148 targets human DNA methyltransferase 3b (DNMT3b) amino acid coding regions [33] . Let-7 miRNA targets the coding region of miRNA processing enzyme, Dicer [34] . Murine Nanog, Oct4 and Sox2 genes contain numerous binding sites in exon coding sequences for naturally occurring miRNAs [35] . These reports suggest that miRNAs target specific gene families within coding regions. Recently, Ponnusamy et al reported that overexpression of MUC4 results in epithelial to mesenchymal transition through down regulation of E-cadherin and increased cancer cell migration and invasion in ovarian cancer cells [36] . These results are consistent with our study, which shows that overexpression of the mesenchymal to epithelial promoting miR-200c down regulates ZEB1 and MUC4 in pancreatic cancer cells.
MUC16 is highly overexpressed in ovarian cancer and moderately overexpressed in pancreatic cancer, but the role of MUC16 in pancreatic cancer progression has not been extensively studied. Several studies have shown that aberrant and increased expression of MUC4 and MUC16 occurs during pancreatic cancer progression to metastasis [17] [18] [19] 25] . Recently, Mohr et al showed miR-200c expression was reduced in primary pancreatic tumor tissues as compared to some metastatic sites [37] . These results generally support the hypothesis that fluctuations in miR-200c contribute to regulation of expression of MUC4 and MUC16 during pancreatic tumor progression and metastases.
In conclusion, our study presents the first evidence that MUC4 and MUC16 are regulated at the post-transcriptional level by a miRNA, miR-200c, which directly targets MUC4 and MUC16 within their amino acid coding regions. These results indicate that miR-200c may have a potential inhibitory role in pancreatic cancer growth and metastasis and additional studies are required to delineate the regulatory relationship between membrane bound mucins and miR-200c. 
